Holen Sie sich die Stockscreener-App
0.7351
1.67%
0.0121
Handel nachbörslich:
.75
0.0149
+2.03%
Invivyd Inc Aktie (IVVD) Neueste Nachrichten
Trading Day Triumph: Invivyd Inc (IVVD) Ends at 0.79, a -6.47 Surge/Plunge - DWinneX
H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall - Insider Monkey
Invivyd stock target cut to $5 by H.C. Wainwright, retains Buy rating - Investing.com Nigeria
Invivyd (NASDAQ:IVVD) Price Target Lowered to $5.00 at HC Wainwright - Defense World
Invivyd (IVVD) Analyst Rating Update: Price Target Lowered | IVV - GuruFocus
Invivyd (IVVD) Price Target Reduced by H.C. Wainwright Amid Revenue Concerns | IVVD Stock News - GuruFocus
Invivyd (IVVD) Publishes Strong Phase 3 Trial Results for COVID-19 Antibody | IVVD Stock News - GuruFocus
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive S - The Manila Times
Breakthrough COVID-19 Drug PEMGARDA Achieves 84% Protection in First Modern U.S. Phase 3 Trial - Stock Titan
Invivyd’s antibody gains spot in cancer guidelines for COVID-19 PrEP By Investing.com - Investing.com South Africa
Invivyd’s antibody gains spot in cancer guidelines for COVID-19 PrEP - Investing.com Australia
Invivyd's Pemgarda Added to NCCN Guidelines in Oncology for B-Cell Lymphomas - marketscreener.com
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas - The Manila Times
Invivyd (IVVD) Monoclonal Antibody Added to NCCN Guidelines for B-Cell Lymphomas | IVVD Stock News - GuruFocus
NCCN Guidelines Now Include PEMGARDA for B-Cell Lymphoma COVID Protection | IVVD Stock News - Stock Titan
Invivyd (IVVD) Applauds FDA's Steps to Address COVID-19 Booster Uncertainty | IVVD Stock News - GuruFocus
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 - The Manila Times
Invivyd Commends FDA on New Framework for COVID-19 Vaccines Amidst Uncertainty Regarding Booster Efficacy - Nasdaq
FDA Questions COVID Booster Benefits While Invivyd's Antibody Shows 84% Protection in Modern Trials - Stock Titan
Invivyd at H.C. Wainwright Conference: Strategic Moves in Antibodies By Investing.com - Investing.com Nigeria
Invivyd Holds Annual Stockholders Meeting, Elects Directors - TipRanks
Invivyd at H.C. Wainwright Conference: Strategic Moves in Antibodies - Investing.com
Upstream Bio Strengthens Leadership Team: Former Invivyd Executive Takes CTO Role for Critical Clinical Program - Stock Titan
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates - MSN
Invivyd (IVVD) Maintains Buy Rating with Stable Price Target | I - GuruFocus
Invivyd, Inc. (NASDAQ:IVVD) Q1 2025 Earnings Call Transcript - Insider Monkey
Invivyd Q1 2025 slides: Revenue grows amid regulatory hurdles and cash concerns - Investing.com Nigeria
Invivyd (IVVD) Maintains Buy Rating with Stable Price Target | IVVD Stock News - GuruFocus
Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss - Investing.com Canada
Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss By Investing.com - Investing.com South Africa
Invivyd Reports Q1 2025 Financial Results and Outlook - TipRanks
Invivyd’s Earnings Call: Strategic Moves Amid Challenges - TipRanks
Why JD.com Stock Slumped on Thursday - The Globe and Mail
INVIVYD SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc.IVVD, A - Barchart.com
Transcript : Invivyd, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Invivyd (IVVD) Reports Q1 Revenue Below Expectations Amid Strate - GuruFocus
Invivyd (IVVD) Reports Q1 Revenue Below Expectations Amid Strategic Shift | IVVD Stock News - GuruFocus
Invivyd Reports Q1 2025 Financial Results and Highlights - TipRanks
INVIVYD Earnings Results: $IVVD Reports Quarterly Earnings - Nasdaq
Invivyd, Inc. SEC 10-Q Report - TradingView
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Invivyd, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Invivyd calls for modernized FDA vaccine guidelines By Investing.com - Investing.com Canada
Invivyd Launches New Measles Antibody Discovery Program: Retail Traders Bet On ‘Future Of Medicine’ - MSN
What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings - Yahoo Finance
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):